Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07389408

A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
National and Kapodistrian University of Athens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is planned to observe and document the therapeutic decision-making process, treatment protocols, and clinical outcomes in patients with luminal breast cancer, whether they have undergone EndoPredict® testing or not

Detailed description

PRELUDE is a prospective, multicenter, non-interventional registry designed to describe real-world treatment decision-making, treatment patterns, and long-term clinical outcomes in patients with luminal (ER-positive/HER2-negative) early breast cancer who are eligible for EndoPredict® testing, including patients who do and do not undergo the test. The registry will be conducted at approximately 10-20 sites across Greece (with the option to add sites outside Greece if needed) and aims to enroll up to 2,000 eligible participants within 3 years. Participants may be enrolled after surgical histopathology results are available and before commencement of adjuvant endocrine treatment, and will be followed prospectively once per year for up to 10 years after surgery. The study aims to assess 5- and 10-year clinical outcomes and to evaluate these outcomes according to EndoPredict® (EP/EPclin) risk groups or scores among patients who undergo testing, in a real-world setting. The registry will also examine which patient and disease characteristics (e.g., age, menopausal status, nodal status, histopathology, EPclin score) will influence adjuvant treatment decisions, in the context of evolving therapeutic standards and recently introduced adjuvant options.

Conditions

Timeline

Start date
2025-04-01
Primary completion
2028-03-31
Completion
2038-12-31
First posted
2026-02-05
Last updated
2026-02-05

Locations

13 sites across 1 country: Greece

Source: ClinicalTrials.gov record NCT07389408. Inclusion in this directory is not an endorsement.